Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?

Eur Urol. 2014 Feb;65(2):504-5. doi: 10.1016/j.eururo.2013.10.035. Epub 2013 Nov 1.

Authors

Arun A Azad¹, Bernhard J Eigl²

Affiliations

¹ Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: [email protected].
² Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.

PMID: 24210911
DOI: 10.1016/j.eururo.2013.10.035

No abstract available

Publication types

Letter

MeSH terms

Abiraterone Acetate
Androstadienes / administration & dosage
Androstadienes / adverse effects*
Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Agents, Hormonal / adverse effects*
Disease Progression
Drug Administration Schedule
Humans
Kallikreins / blood*
Male
Prostate-Specific Antigen / blood*
Prostatic Neoplasms, Castration-Resistant / blood
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / pathology
Retrospective Studies
Risk Factors
Substance Withdrawal Syndrome / blood
Substance Withdrawal Syndrome / diagnosis
Substance Withdrawal Syndrome / etiology*
Time Factors

Substances

Androstadienes
Antineoplastic Agents, Hormonal
KLK3 protein, human
Kallikreins
Prostate-Specific Antigen
Abiraterone Acetate